The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
Unresectable Colorectal Cancer
DRUG: ONO-7913|DRUG: ONO-4538|DRUG: Fluorouracil|DRUG: Oxaliplatin|DRUG: Levofolinate|DRUG: Bevacizumab|DRUG: Cetuximab
Dose-limiting toxicities（DLT）, 28 days|Adverse event (AE), Up to 30 days after the last dose
Pharmacokinetics（Plasma concentration of ONO-7913）, Through study completion, an average of 1 year.|Pharmacokinetics（Plasma concentration of ONO-4538）, Through study completion, an average of 1 year.|Objective Response Rate (ORR), Through study completion, an average of 1 year.|Disease Control Rate (DCR), Through study completion, an average of 1 year.|Overall Survival (OS), Through study completion, an average of 3 years.|Progression-Free Survival (PFS), Through study completion, an average of 1 years.|Duration of Response (DOR), Through study completion, an average of 1 years.|Time to Response (TTR), Through study completion, an average of 1 years.|Best Overall Response (BOR), Through study completion, an average of 1 years.|Percent change in the sum diameters of the target lesions, Through study completion, an average of 1 years.|Maximum percent change in the sum diameters of the target lesions, Through study completion, an average of 1 years.|Early Tumor shrinkage（ETS）, Up to 8 weeks|Change From Baseline in Tumour Biomarkers (CEA and CA19-9), Through study completion, an average of 1 year.
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer